Background {#Sec1}
==========

Obesity is a metabolic disorder and the fundamental cause of other fatal diseases including atherosclerosis, hypertension, diabetes, premature aging and cancer \[[@CR1]\]. A high fat diet causes diseases such as obesity and changes the DNA gene expression profile \[[@CR2]--[@CR4]\].Scheme 1Animal experimental design

Cricket (*Gryllus bimaculatus*) water extract is used in Oriental medicine as a crude drug for treating fever and hypertension, and crickets are currently reared as food for pets \[[@CR5]\]. The main components of *G. bimaculatus* are protein (52.81 %), ash (minerals) and fat (21.81 %), including rich essential unsaturated conjugated fatty acids -- such as palmitic acid (ω-7, 34.14 %), oleic acid (ω-9, 36.48 %), and linoleic acid (ω-6, 13.58 %) \[[@CR6]\]. Water and methanol extracts from crickets were recently found to cause a significant decrease in blood ethanol concentrations by enhancing liver mitochondrial alcohol metabolizing enzymes \[[@CR7]\]. The extracts also had protective effects against acute hepatic damage \[[@CR8]\].

The fact that *G. bimaculatus* is abundant in unsaturated fatty acid and decrease of omega-6/omega-3 fatty acid ratio when fed to chickens suggest that *G. bimaculatus* may reduce fat or increase unsaturated fatty acid ratio in tissues \[[@CR6]\]. The antioxidant effect of GB reported in previous studies may relieve the obese state or obese-related disorders. Recent studies report anti-obesity and anti-diabetic effects are *Isaria sinclairii* (Cicada Dongchunghacho, a fungus cultured on silkworm) \[[@CR9]--[@CR11]\]. Pravastatin (a type of statins), lipid-lowering drug, especially hydroxymethylglutaryl-CoA reductase inhibitor, is widely used in the treatment and prevention of atherosclerotic diseases \[[@CR12]\]. Therefore, we assessed the effects of GB compared its antilipidemic activity with *I. sinclarii* ethanol extract or Pravastain as positive controls. In this study, the fatty acid composition in abdominal fat tissue and epididymidal tissue of Wistar rats treated with GB was evaluated and compared to *Isaria sinclaii* \[[@CR10]\] extract (IS100) and pravastatin (STA). A high fat diet (HFD) also can cause oxidative stress and was due to lipid peroxidation (malon dialdehyde increase), protein carbonyl content increase, and DNA damage.

We report the sero-biochemical and DNA micro array study of GB in HFD Wistar rats with regard to preventing oxidative stress to proteins, lipids and DNA. This GB holds great promise for use as an anti-obesity drug to decrease fat accumulation in people on high fat diets and prevent changes in liver fat. We demonstrate the potential efficacy of GB in the treatment of anti-lipidemic effect on a HFD rats to be a protective nutraceutical for atherosclerosis disorders, including circulatory disorders, showing gene expression profile with valuable prognostic marker to identify potential therapeutic targets for atherosclerosis and obesity.

Results {#Sec2}
=======

Clinical sign and food consumption {#Sec3}
----------------------------------

No deaths or adverse clinical signs were apparent due to the ingestion of the *G. bimaculatus* extract or pravastatin. The level of food consumption was similar in all treated groups during the course of the study (Fig. [1](#Fig1){ref-type="fig"}). Mean daily food intake was 26.6 g/kg bw/day.Fig. 1Food consumption changes in Wistar rats treated with GB on a high fat diet

Body weight and adipose fat weight changes {#Sec4}
------------------------------------------

There were no toxicologically significant differences in mean body weight between any of the treatment groups (Fig. [2a](#Fig2){ref-type="fig"}). During the 1-month administration period, the body weights of the male Wistar rats in the 2 treatment groups were comparable in the control and trexperimental groups. The mean weekly body weights over time are presented in Fig. [2a](#Fig2){ref-type="fig"}. However, about 2 months after the experiment, body weight deviation between the groups increased, especially with the IS100 group. The body weight of the IS100 group continued to decrease for some time. The body weight of the IS100 group was significantly different from that of the control group (*p* \< 0.05). At sacrifice, the abdominal fat tissues and the epididymidal fat tissues were dissected and weighed to investigate adipose tissue changes. The abdominal fat weight of HFD rats was significantly reduced by *G. bimaculatus* extract (200 mg/kg) (GB200) after 2 months of treatment: Con, 19.16 ± 3.04 g; GB100, 16.37 ± 1.46 (85.4 %); GB 200, 13.03 ± 1.37 g (68.0 %, GB200 vs Con, *p* \< 0.05). Figure [2b](#Fig2){ref-type="fig"} also shows the declineof abdominal and epididymidal fat weight in HFD rats treated with GB for 1 month. The relative weight of epididymidal fat tissuedecreased to 75.0 % in GB200 after1 month of treatment. The total fat in GB100 and GB200 decreased by 77.9 and 73 % comparedto the CON (Fig. [2b](#Fig2){ref-type="fig"}). The fat-reducing effect of GB extract was better than that of pravastatin (STA) in rats.Fig. 2**a** Effect of GB on body weight in high fat (60 %) dieted rat over 2 months. GB100 (200): *G. bimaculatus* ethanol extract 100 (200) mg/kg. STA: Pravastatin 2 mg/kg. IS100: *I. sinclairii* ethanol extract 100 mg/kg. \*: significant differences compared with CON group (\**p* \< 0.05). **b** Effect of GB (1 month treatment) on abdominal and epididymidal fat weight on a high fat diet. \*: significant differences compared with CON group (\**p* \< 0.05, \*\*\**p* \< 0.001)

Serum biochemical analysis {#Sec5}
--------------------------

The changes in serum lipid and lipoprotein profiles after the 1-mo. feeding period are show in Table [1](#Tab1){ref-type="table"}.Table 1Serological findings for ethanol extract from cricket in Wistar rats on high fat diet over a 1-month treatment periodItemUnitCONGB100STAIS100phospholipidmg/dL151.50 ± 17.06152.00 ± 19.95178.80 ± 20.20123.40 ± 10.48FFAmEq/L507.75 ± 45.46465.75 ± 57.94532.40 ± 81.22526.20 ± 126.11InsulinmU/ml\<0.2 ± 0.0\<0.2 ± 0.0\<0.2 ± 0.0\<0.2 ± 0.0Albuming/dL4.05 ± 0.243.37 ± 0.213.94 ± 0.253.48 ± 0.260T. Bilmg/dL0.125 ± 0.050.1 ± 00.1 ± 0.00.14 ± 0.09ALPIU/L133.25 ± 40.4679.75 ± 13.43107.50 ± 63.16168.60 ± 106.11ASTIU/L100.5 ± 14.30143 ± 96.23116.61 ± 9.36168.33 ± 25.0ALTIU/L41 ± 6.4871.25 ± 67.8649.80 ± 10.23100.80 ± 80.83IPmg/dL21.48 ± 2.0714.60 ± 2.32^a^14.66 ± 1.3411.14 ± 1.88yGTg/dL\<0.3 ± 0.0\<0.3 ± 0.0\<0.3 ± 0.0\<0.3 ± 0.0CKIU/L257.5 ± 79.37205.50 ± 44.35377.60 ± 88.71236.00 ± 93.74LDHIU/L1475.25 ± 311.351206.75 ± 375.441567.20 ± 344.291342.00 ± 344.95Glucose(S)mg/dL340.75 ± 26.48225.00 ± 49.03317.00 ± 85.46213.40 ± 52.18T. Cholmg/dL105.5 ± 7.33110.25 ± 21.04117.80 ± 22.4083.80 ± 12.28TGmg/dL167 ± 33.97112.75 ± 20.2151.60 ± 53.3591.80 ± 40.44LDL Cholmg/dL22.25 ± 4.3432.25 ± 10.3724.80 ± 9.2018.00 ± 6.52BUNmg/dL23.55 ± 1.2516.2 ± 2.2022.42 ± 2.2727.68 ± 5.18HDL Cholmg/dL79 ± 7.7573.5 ± 7.0588.20 ± 15.7463.80 ± 12.99Creatininemg/dL0.59 ± 0.040.501 ± 0.090.61 ± 0.090.86 ± 0.15Uric acidmg/dL6.18 ± 1.715.33 ± 0.225.48 ± 1.445.88 ± 0.84Nanmol/L127.25 ± 4.65133.75 ± 5.68133.40 ± 2.61133.80 ± 2.78Knmol/L26.78 ± 8.7320.13 ± 4.0221.04 ± 1.8518.86 ± 2.96Clnmol/L93.5 ± 2.8995.00 ± 3.1695.20 ± 2.5994.40 ± 2.61T. proteing/dL6.75 ± 0.56.35 ± 0.426.54 ± 0.396.38 ± 0.47CRP(HS)mg/L1.68 ± 0.050.53 ± 0.251.58 ± 0.401.16 ± 0.50Calciumnmol/L12.40 ± 0.6411.90 ± 0.6212.34 ± 0.8712.12 ± 0.40*FFA* free fatty acid, T. *Bil* total bilirubin, *ALP* alkaline phosphatase, *AST(GOT)* glutamate oxaloacetate transaminase, *ALT(GPT)* glutamate pyruvate transaminase, *IP* inorganic phosphorus, *GGT γ*-glutamyl transferase, *CK* creatinine phosphokinase, *LDH* lactate dehydrogenase, *Na* Sodium, *K* potassium, *Cl* chloride, *BUN* blood urea nitrogen, *T. Chol* total cholesterol, *TG* triglyceride, *H. Chol* high cholesterol, *l.Chol* low cholesterol, *Ca* calcium, *CRP* c-reactive proteinEach value represents mean ± S.D. Statistically significant from control (^\*^ *P* \< 0.05)CON: PBS (vehicle) treated with murine high fat diet

The data obtained clearly show that high-fat diet ingestion increased the concentration of serum triglyceride and serum triglyceride was decreased in the GB100 experimental rats \[control, 167.00 ± 33.97 mg/dL; GB100, 112.75 ± 20.2 mg/dL (GB100 *vs* Con *p* \< 0.05); STA, 151.60 ± 53.35 mg/dL\]. Serum glucose levels were lower in the GB-treated group than in the control Serum glucose levels were lower in the GB-treated group than in the control (control, 340.75 ± 26.48 mg/dL; GB100, 225.00 ± 49.03 mg/dL (GB100 *vs* Con, *p* \< 0.05); Provastastin (STA), 317.00 ± 85.46 mg/dL; IS100, 213.40 ± 52.18 mg/dL). Analysis of C-reactive protein (CRP) levels showed meaningful anti-edema effect with the inhibition of CRP, but the results had no significance (control, 1.68 ± 0.05 mg/L; GB100, 0.53 ± 0.25 mg/L; STA, 1.58 ± 0.40 mg/L; IS100, 1.16 ± 0.5 mg/L). Also, in the sera of GB100-treated rats, free fatty acid (FFA) levels were lower than in the control (control 507.75 ± 4.46 mEq/L; GB100, 465.75 ± 57.094 mEq/L; STA, 532.40 ± 81.22 mEq/L; IS100 526.20 ± 126.11 mEq/L). Triglyceride levels were significantly lower in the GB treated rats compared to the control as follows: control, 167.0 ± 33.97 mg/dL; GB100, 112.75 ± 20.2 mg/dL (GB100 *vs* CON, *p* \< 0.05); STA, 151.60 ± 53.35 mg/dL; IS100, 91.80 ± 40.44 mg/dL. The alkaline phosphatase (ALP) levels of the treated groups were lower in the high fat diet fed rats (control, 133.25 ± 40.46; GB100, 79.75 ± 13.43 (control, 133.25 ± 40.46 IU/L; GB100, 79.75 ± 13.43 IU/L (GB100 *vs* CON, *p* \< 0.05); STA, 107.50 ± 63.16 IU/L; IS100, 168.60 ± 106.11 IU/L.

The changes in serum lipid and lipoprotein profiles in HFD rats after GB 2 months of treatment are show in Table [2](#Tab2){ref-type="table"}.Table 2Serological findings for GB in Wistar rats on high fat diet over a 2-month treatment periodItemUnitCONGB100GB200STAIS100Total proteing/dL6.63 ± 0.186.75 ± 0.556.95 ± 0.186.84 ± 0.157.00 ± 0.11Bilirubinmg/dLbelow 0.1below 0.1below 0.1below 0.1below 0.1ALPU/L38.67 ± 4.7338.00 ± 4.2442.75 ± 7.1439.00 ± 3.1642.75 ± 8.26ASTU/L145.00 ± 28.58128.50 ± 21.92144.00 ± 98.1896.60 ± 18.23122.50 ± 51.86ALTU/L46.67 ± 1.5347.50 ± 10.6181.75 ± 33.3136.60 ± 13.1328.50 ± 4.36GGTU/Lbelow 3below 3below 3below 3below 3CKU/L607.00 ± 188.07438.00 ± 61.00676.25 ± 203.71382.00 ± 36.56256.00 ± 37.45LDHU/L1577.33 ± 241.141830.50 ± 281.501897.25 ± 273.261179.00 ± 202.53916.50 ± 93.39Nammol/L148.50 ± 1.32151.50 ± 1.50147.75 ± 1.31147.40 ± 0.40145.25 ± 0.85Kmmol/L11.20 ± 1.199.40 ± 2.4010.68 ± 1.189.24 ± 0.9510.43 ± 0.81Clmmol/L97.00 ± 1.0899.00 ± 3.0096.75 ± 1.4998.40 ± 0.8797.25 ± 1.03Creatinemg/dL0.80 ± 0.030.69 ± 0.120.79 ± 0.050.72 ± 0.030.92 ± 0.06BUNmg/dL16.57 ± 0.2717.00 ± 0.0019.78 ± 1.2913.92 ± 0.4625.73 ± 2.41Uric acidmg/dL3.83 ± 0.487.85 ± 0.556.53 ± 0.476.08 ± 0.565.90 ± 0.33T.Cholmg/dL106.00 ± 8.08110.50 ± 24.5093.00 ± 3.6184.40 ± 3.37100.75 ± 8.00H.Cholmg/dL89.67 ± 6.1795.50 ± 18.5079.67 ± 2.4074.60 ± 2.5889.25 ± 6.16L.Cholmg/dL21.00 ± 2.0021.00 ± 17.6717.67 ± 0.6715.60 ± 0.8120.00 ± 2.12TGmg/dL100.50 ± 11.86100.50 ± 0.50101.33 ± 20.0287.20 ± 9.2554.25 ± 4.01Glucosemg/dL187.67 ± 2.19163.00 ± 18.00192.75 ± 67.45252.00 ± 29.43198.75 ± 30.38Camg/dL11.57 ± 0.0711.70 ± 0.7012.05 ± 0.3712.30 ± 0.4212.53 ± 0.37IPmg/dL21.10 ± 1.0719.25 ± 2.2519.68 ± 1.7714.44 ± 1.6011.18 ± 0.85FFAuEq/L907.49 ± 191.701071.50 ± 42.50931.00 ± 81.12855.00 ± 122.43738.00 ± 51.22Each value represents mean ± S.E. statistically significant from control (^\*^ *P* \< 0.05)

The obtained data clearly show that high-fat diet consumption increased the concentration of serum total cholesterol, TG, and LDL-cholesterol in addition to decreasing the HDL-cholesterol concentrations in the experimental rats after 2 months of treatment. Total cholesterol, LDL- cholesterol, TG, and total lipid in the GB-treated group were lower than in the control group. HDL-cholesterol in the GB-treated group was higher than in the control group.

Serum glucose levels were lower in the GB-treated group than in the control (control, 187.67 ± 2.19 mg/dL; GB100, 163.00 ± 18.00 mg/dL; GB200, 192.75 ± 67.45 mg/dL; STA, 252.00 ± 29.43 mg/dL (STA *vs* CON, *p* \< 0.05); IS100, 198.75 ± 30.38 mg/dL). In the sera of the GB treated groups, total cholesterol, LDL-cholesterol and triglyceride levels were lower, while HDL-cholesterol was higher than in the control after 2 months. Dose-dependent changes were observed in rats on high-fat diets although there were no significant differences compared with the control group (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Effect of GB on serum total cholesterol, triglyceride and HDL-cholesterol level in High fat diet rats (2 month GB treatment)

Hematology and blood chemical analysis {#Sec6}
--------------------------------------

Some dose-dependent changes were observed between the treated and control groups with respect to the hematological parameters at the end of the experiment. An increase in partial thromboplastin time and thrombin time was observed in the treated groups on high fat diets but without significant differences. Minor changes were found in hematological parameters (hematocrit, MCV, MCHC and factor I) for some GB-treated rat groups. However, the effects of GB were not considered adverse because all changes in hematological data including neutrophil, lymphocyte, monocyte and eosinophil were within the normal physiological range. The platelet count of the IS100 group was increased compared to the CON group (*p* \< 0.05) (Table [3](#Tab3){ref-type="table"}).Table 3Hematological findings for extract from cricket in Wistar rats on high fat diet over a 2-month treatment periodUnitCONGB100GB200STAIS100WBC10^3^/μl535 ± 0.546.67 ± 1.566.28 ± 0.754.60 ± 0.357.3 ± 0.56RBC10μl8.15 ± 0.098.65 ± 0.719.04 ± 0.208.83 ± 0.198.56 ± 0.11Hgbg/dL1496 ± 0.2915.10 ± 0.5015.75 ± 0.2215.78 ± 0.2014.83 ± 0.09Hct%50.16 ± 1.0151.50 ± 2.6053.68 ± 0.8853.26 ± 0.7649.65 ± 0.43MCVfL6156 ± 1.1559.70 ± 1.9059.43 ± 0.7260.40 ± 0.7658.03 ± 0.95MCHpg18.18 ± 0.4917.55 ± 0.8517.40 ± 0.3617.92 ± 0.2417.30 ± 0.30MCHCg/dL29.84 ± 0.2529.35 ± 0.4529.30 ± 0.2729.64 ± 0.1629.85 ± 0.14PLT10^3^/μl974.00 ± 67.06938.50 ± 216.501044.00 ± 63.44954.80 ± 38.771240.25 ± 24.32PTTsec98.06 ± 18.58107.80 ± 36.2076.03 ± 11.1374.70 ± 7.2659.50 ± 12.03Thrombin timesec60.10 ± 13.6963.40 ± 22.1053.40 ± 11.0647.70 ± 6.0850.90 ± 9.49Factor Img/dL194.00 ± 3012216.50 ± 9.50245.75 ± 18.36214.60 ± 26.21247.75 ± 13.03PTsce5.66 ± 0.161.59 ± 0.111.53 ± 0.041.48 ± 0.061.46 ± 0.07Neutrophil%21.70 ± 33413.10 ± 0.6016.83 ± 2.2816.72 ± 1.6618.23 ± 1.89Lymphocyte%75.43 ± UJ oo85.55 ± 0.5581.48 ± 2.4981.22 ± 1.8479.78 ± 2.08Monocyte%0.90 ± 0.190.35 ± 0.050.43 ± 0.140.64 ± 0.100.68 ± 0.19Eosinophil%1.62 ± 0.130.85 ± 0.051.03 ± 0.131.04 ± 0.150.88 ± 0.08Basophil%0.34 ± 0.080.15 ± 0.050.25 ± 0.060.38 ± 0.07158 ± 1.14*WBC* white blood cell, *RBC* red blood cell, *Hgb* hemoglobin, *Hct* hematocrit, *MCV* mean corpuscular volume, *MCH* mean corpuscular hemoglobin, *MCHC* mean corpuscular hemoglobin concentration, *PLT* partial thromboplastin time, *PT* prothrombin timeCON: PBS (as a vehicle) treated with high fat dietEach value represents mean ± S.E. Statistically significant from control (*P*\* \< 0.05)

Oxidative protein damage (carbonyl content and catalase) quantitation {#Sec7}
---------------------------------------------------------------------

Protein oxidative stress was evaluated by measuring protein carbonyl content in the blood (Fig. [4](#Fig4){ref-type="fig"}). Catalase activity and carbonyl content were assayed as the biomarkers of protein oxidative damage in the high fat dieted rat model.Fig. 4Anti-oxidative effect of GB on lipids (MDA or IL-6) and proteins (carbonyl or catalase content) after 2-month treatment. Each value represents mean ± S.D. statistically significant from control (\*P \< 0.05)

After 2 months, carbonyl content level was decreased by GB treatment: CON, 12.6 ± 1.1 nmol/mg protein; GB100, 10.4 ± 2.7 nmol/mg protein; GB200 (GB200 *vs* CON, *P* \< 0.05), 6.8 ± 2.8 nmol/mg protein; STA, 9.8 ± 4.0 nmol/mg protein; IS100, 5.1 ± 1.6 nmol/mg protein (IS100 *vs* CON, *P* \< 0.05). The protein carbonyl content in the blood was reduced in a dose-dependent manner after extract treatments for 2 months. The protein carbonyl concentration was decreased by 82 and 53 % in GB100 and GB200, respectively (Fig. [4](#Fig4){ref-type="fig"}).

The catalase activity (Ug/protein) after 2 months of GB treatment was as follows: CON, 0.016 ± 0.001 U/mg protein; GB100, 0.017 ± 0.004 U/mg protein; GB200, 0.014 ± 0.001 U/mg protein; STA (2 mg/kg), 0.014 ± 0.002 U/mg protein; IS100, 0.016 ± 0.002 U/mg protein in hepatocytes (Fig. [4](#Fig4){ref-type="fig"}). The catalase activity in all hepatocyte groups was not affected.

Oxidative lipid damage (malondialdehyde) quantitation {#Sec8}
-----------------------------------------------------

As a lipid oxidative damage marker in lipid oxidative stress states, malondialdehyde level (MDA, nmol/mg/protein) was assayed after 2 months of GB treatment: PBS (CON), 3.44 ± 0.47 nmol/mg/protein; GB 100, 0.23 ± 0.31 (GB100 *vs* CON, *p* \< 0.05) nmol/mg/protein, GB 200, 1.92 ± 0.87 nmol/mg/protein (GB200 *vs* CON, *p* \< 0.05); STA, 2.83 ± 1.33 nmol/mg/protein; IS100, 3.00 ± 0.22 nmol/mg/protein (Fig. [4](#Fig4){ref-type="fig"}). Pravastatin (STA) and IS100 did not affect the lipid peroxidation in hepatocytes.

Cytokine IL-10 production {#Sec9}
-------------------------

Decrease of serum IL-10 level was observed in the GB-treated group. IL-10 activity after 2 months of GB treatment in HFD rat serum was as follows: PBS: 670.5 ± 96.1 pg/ml serum, GB 100: 492.0 ± 66.6 pg/ml serum (GB100 *vs* CON, *p* \< 0.05), GB 200: 598.1 ± 51.8 pg/ml serum, STA: 590.7 ± 12.2 pg/ml serum, IS100: 862.4 ± 126.6 pg/ml serum (Fig. [4](#Fig4){ref-type="fig"}). STA and IS100 had no statistical differences compared with the CON group.

DNA microarray {#Sec10}
--------------

Microarray analysis using a Mouse 28 K cDNA clone set array was performed to identify the gene-expression profiles in the GB treated Wistar rat livers and provided information on potential markers for atherosclerosis. Compared to the control group, the GB treated rats showed 419 (200 mg/kg) and 430 (100 mg/kg) up-regulated genes (15 % increase), and the signal ratio increased from 1.15-fold to 3.28-fold. Gpm6a (glycoprotein m6a), Tmem14a (transmembrane protein 14A) and Fasin (fatty acid synthase) were up-regulated and 421 genes (ratio 0.47 \~ 0.85) including Cc121b (chemokine ligand 21b), Glycan1 (glycosylation dependent cell adhesion moleule, Serpinb1a (serine proteinase inhibitor) and Tcrb (T-cell receptor beta chain) were down-regulated. The data suggests that Fasin related fatty acid synthesis and Adfp, an adipose differentiation related protein associated with obesity, were upregulated by GB treatment. However, a series of genes involved in signal transduction, fatty acid synthesis, energy metabolism (oxidative metabolism) and cellular defenses were more up-regulated, indicating their potential as therapeutic markers for lipid metabolism (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}).Table 4Upregulated genes differentially expressed in liver tissue of high fat diet rats treated with *G. bimaculatus* extract over a 1-month periodG100^a^G200^b^Gene titleGene symbol10.8911.916glycoprotein m6aGpm6a20.9571.767transmembrane protein 14ATmem14a31.3001.416fatty acid synthaseFasn40.9931.396RT1 class I, locus CE5RT1-CE551.3701.393ubiquitin-like modifier activating enzyme 5Uba560.6171.372RT1 class Ib, locus EC2RT1-EC271.1011.358TWIST neighborTwistnb81.3031.345coagulation factor C homolog, cochlinCoch91.4971.343X-linked Kx blood group (McLeod syndrome) homologXk101.1711.341dedicator of cytokinesis 11Dock11110.9451.335amyloid beta (A4) precursor-like protein 1Aplp1120.8531.334D site of albumin promoter binding proteinDbp130.7941.326RT1 class I, locus CE11-like /// RT1 class I, locus A3LOC100364500141.8601.319Sumo1/sentrin/SMT3 specific peptidase 5Senp5151.1251.316platelet-activating factor acetylhydrolase, isoform 1bPafah1b1161.0321.306isoprenoid synthase domain containingIspd171.1631.288osteoglycinOgn181.2731.280myxovirus (influenza virus) resistance 2Mx2190.9571.276similar to KIAA0802 proteinRGD1308319201.1701.276echinoderm microtubule associated protein like 2Eml2211.0611.275Rab40b, member RAS oncogene familyRab40b221.0991.268Complement component 1, q subcomponent-like 3C1ql3231.3991.266family with sequence similarity 135, member AFam135a241.3771.266Adipose differentiation related proteinAdfp251.0911.264acylphosphatase 2, muscle typeAcyp2261.0581.259RAD23 homolog B (S. cerevisiae)Rad23b271.1411.258cytochrome P450, family 4, subfamily v, polypeptide 3Cyp4v3281.1131.256OpticinOptc290.9611.255ubiquitin DUbd301.0381.253nucleosome assembly protein 1-like 3Nap1l3311.1681.252protocadherin alpha 1 /// protocadherin alpha 10Pcdha1321.1831.251similar to CG12279-PALOC500420331.0581.249solute carrier family 31 (copper transporters), member 1Slc31a1340.9791.248stem-loop binding proteinSlbp351.0261.242O-sialoglycoprotein endopeptidase-like 1Osgepl1361.0601.240ring finger protein 141rnf141371.0061.240caveolin 2 /// caveolin 2-likeCav2381.0251.240major facilitator superfamily domain containing 9Mfsd9390.9911.238chemokine (C-X-C motif) ligand 9Cxcl9401.2371.237protein phosphatase 4, regulatory subunit 2Ppp4r2^a^GB100/control ratio^b^GB200/control ratioTable 5Downregulated genes differentially expressed in liver tissue of high fat diet rats treated with GB over a 1-month periodGB100^a^GB200^b^Gene titleGene symbol10.4780.472chemokine (C-C motif) ligand 21bCcl21b20.5630.563glycosylation dependent cell adhesion molecule 1Glycam130.6100.583serine (or cysteine) proteinase inhibitor, clade B, member Serpinb1a40.6250.599T-cell receptor beta chainTcrb50.7550.618Lymphoid enhancer binding factor 1Lef160.6150.646T-cell receptor beta chainTcrb70.6460.658immunoglobulin heavy chain 6Igh-680.6990.658CD3 molecule, gamma polypeptideCd3g90.6800.680coronin, actin binding protein 1ACoro1a100.6870.687SATB homeobox 1Satb1110.6230.695similar to RIKEN cDNA A430107P09LOC100364854120.7170.701Fas apoptotic inhibitory molecule 3Faim3130.7030.715lumicanLum140.9240.722interleukin 7 receptorIl7r150.8150.731SATB homeobox 1Satb1160.8690.740CD3 molecule, epsilon polypeptideCd3e170.8190.742ADP-ribosylation factor-like 5CArl5c180.7490.749protein tyrosine phosphatase, receptor type, CPtprc190.8890.755cancer susceptibility candidate 1Casc1200.8790.758LIM domain containing 2Limd2210.9010.760bromodomain containing 4Brd4221.0070.764proenkephalinPenk230.7760.765hypothetical protein LOC100364588LOC100364588240.9150.768phospholipase D1Pld1250.7770.769immunoglobulin joining chainIgj260.9410.769sodium channel, voltage-gated, type IV, alpha subunitScn4a270.8060.770Zinc finger protein 710Znf710280.7290.770thyroid hormone receptor betaThrb290.9260.774transition protein 2Tnp2300.8220.774SWI/SNF-related matrix-aa-dependent regulator of c2LOC685179310.9580.774protocadherin gamma subfamily A, 1Pcdhga1320.8210.776tubulin, beta 2cTubb2c330.9380.776galanin receptor 2Galr2340.8380.777matrix metallopeptidase 12Mmp12350.7770.777SAM and SH3 domain containing 3Sash3360.7710.777TBC1 domain family, member 10CTbc1d10c370.9810.7792′-5′-oligoadenylate synthetase-likeOasl380.7640.779similar to immunoglobulin light chain variable regionRGD1564318390.8120.779POU class 2 associating factor 1Pou2af1400.7830.783CD3 molecule delta polypeptideCd3d^a^GB100/control ratio^b^GB200/control ratio

Fatty acid composition in adipose tissue {#Sec11}
----------------------------------------

The fatty acid profile, as indicated GC-MS, showed a slight dose-dependent increase in arachidonic acid (C20: 4n6, AFA) concentration in the epididymidal of male Wistar rats in the GB- treated groups over a 2-month period compared to the control group (Table [6](#Tab6){ref-type="table"}). The high fat dieted Wistar rats treated with GB showed increases in the unsaturated fatty acids (FA) ratio, especially single (mono) FA, but had decreases in saturated fatty acid (Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}).Table 6Analysis of fatty acid composition in abdominal fat of Wistar rats on high fat diets treated with *G. bimaculatus* extract for 1 monthComp. of abdominal fat tissue (%)PBSGB100GB200STAIS100Lauric acid (C12:0)0.04 ± 0.000.05 ± 0.00\*0.05 ± 0.000.05 ± 0.00\*0.04 ± 0.00Myristoleic acid (C14:1)0.02 ± 0.000.02 ± 0.000.02 ± 0.00\*0.02 ± 0.000.02 ± 0.00Myristic acid (C14:0)0.72 ± 0.030.74 ± 0.040.64 ± 0.130.66 ± 0.020.69 ± 0.01Pentadecanoic acid (C15:0)0.12 ± 0.000.12 ± 0.000.24 ± 0.120.12 ± 0.000.12 ± 0.01Palmitoleic acid (C16:1)1.37 ± 0.141.52 ± 0.221.76 ± 0.07\*1.18 ± 0.171.31 ± 0.04Palmitic acid (C16:0)21.49 ± 0.4921.42 ± 0.5921.46 ± 0.3921.20 ± 0.1420.85 ± 0.17Heptadecanoic acid (C17:0)0.29 ± 0.010.28 ± 0.010.29 ± 0.010.33 ± 0.01\*0.30 ± 0.01Linoleic acid (C18:2)34.37 ± 2.8035.24 ± 0.9135.50 ± 0.2731.56 ± 0.9234.70 ± 0.90Oleic acid (C18:1)33.56 ± 2.3532.94 ± 0.8932.33 ± 0.5735.84 ± 0.8833.79 ± 0.89Stearic acid (C18:0)6.92 ± 0.136.72 ± 0.376.75 ± 0.177.90 ± 0.21\*7.09 ± 0.20Arachidonic acid (C20:4)0.20 ± 0.060.14 ± 0.020.13 ± 0.010.19 ± 0.000.19 ± 0.04Eicosapentaenoic acid (C20:5)0.02 ± 0.000.02 ± 0.000.02 ± 0.000.03 ± 0.000.01 ± 0.00Eicosatrienoic acid (C20:3)0.06 ± 0.010.05 ± 0.010.05 ± 0.000.06 ± 0.000.06 ± 0.01Eicosadienoic acid (C20:2)0.25 ± 0.000.25 ± 0.030.24 ± 0.010.29 ± 0.00\*0.24 ± 0.01Eicosenoic acid (C20:1)0.37 ± 0.010.38 ± 0.040.39 ± 0.010.43 ± 0.01\*0.41 ± 0.01Eicosanoic acid (C20:0)0.09 ± 0.010.09 ± 0.010.09 ± 0.010.10 ± 0.000.10 ± 0.01Docosahexaenoic acid (C22:6)0.11 ± 0.080.04 ± 0.000.04 ± 0.000.04 ± 0.010.09 ± 0.04Saturated fatty acid29.66 ± 0.5929.41 ± 0.3929.52 ± 0.4030.36 ± 0.1829.19 ± 0.28Unsaturated fatty acid70.34 ± 0.5970.59 ± 0.3970.48 ± 0.4069.64 ± 0.1870.81 ± 0.28Single unsaturated fatty acid35.33 ± 1.0634.86 ± 1.2234.50 ± 2.5337.47 ± 2.2335.52 ± 0.42Poly unsaturated fatty acid35.02 ± 2.7335.73 ± 0.8835.98 ± 0.2932.16 ± 0.9335.29 ± 0.93Comp. of epididymidal fat tissue (%)PBSGB100GB200STAIS100Lauric acid (C12:0)0.04 ± 0.000.04 ± 0.000.04 ± 0.000.05 ± 0.000.04 ± 0.00Myristoleic acid (C14:1)0.02 ± 0.000.03 ± 0.000.03 ± 0.000.03 ± 0.000.03 ± 0.00Myristic acid (C14:0)0.70 ± 0.040.78 ± 0.020.74 ± 0.010.75 ± 0.010.73 ± 0.03Pentadecanoic acid (C15:0)0.12 ± 0.010.14 ± 0.010.14 ± 0.00\*0.13 ± 0.000.14 ± 0.01Palmitoleic acid (C16:1)1.66 ± 0.151.77 ± 0.071.83 ± 0.051.76 ± 0.061.73 ± 0.11Palmitic acid (C16:0)21.89 ± 0.4021.82 ± 0.1721.95 ± 0.2120.66 ± 0.20\*20.73 ± 0.12Heptadecanoic acid (C17:0)0.26 ± 0.010.27 ± 0.010.27 ± 0.000.28 ± 0.010.28 ± 0.01Linoleic acid (C18:2)36.05 ± 0.9638.21 ± 1.1937.86 ± 0.6039.68 ± 1.24\*38.29 ± 0.08Oleic acid (C18:1)32.41 ± 0.6530.19 ± 1.2330.69 ± 0.5229.48 ± 1.00\*31.27 ± 0.27Stearic acid (C18:0)5.94 ± 0.075.87 ± 0.095.57 ± 0.07\*6.14 ± 0.135.75 ± 0.03Arachidonic acid (C20:4)0.16 ± 0.010.13 ± 0.030.15 ± 0.000.21 ± 0.030.19 ± 0.01Eicosapentaenoic acid (C20:5)0.01 ± 0.010.02 ± 0.010.03 ± 0.00\*0.03 ± 0.00\*0.03 ± 0.00Eicosatrienoic acid (C20:3)0.06 ± 0.000.06 ± 0.000.05 ± 0.000.07 ± 0.000.07 ± 0.01Eicosadienoic acid (C20:2)0.25 ± 0.010.25 ± 0.010.23 ± 0.010.28 ± 0.010.27 ± 0.02Eicosenoic acid (C20:1)0.33 ± 0.010.32 ± 0.010.30 ± 0.00\*0.34 ± 0.010.33 ± 0.01Eicosanoic acid (C20:0)0.06 ± 0.000.06 ± 0.000.06 ± 0.000.06 ± 0.000.05 ± 0.00Docosahexaenoic acid (C22:6)0.03 ± 0.000.04 ± 0.000.06 ± 0.00\*0.06 ± 0.020.07 ± 0.00\*Saturated fatty acid29.01 ± 0.3828.98 ± 0.1828.76 ± 0.1628.06 ± 0.3227.71 ± 0.16Unsaturated fatty acid70.99 ± 0.3871.02 ± 0.1871.24 ± 0.1671.94 ± 0.3272.29 ± 0.16Single unsaturated fatty acid34.42 ± 0.7132.32 ± 1.2632.86 ± 0.5431.61 ± 0.9733.36 ± 0.15Poly unsaturated fatty acid36.57 ± 0.9738.71 ± 1.1538.38 ± 0.5940.33 ± 1.2938.93 ± 0.05Each value represents mean ± SEAsterisk marks (\*) mean significant differences compared with control (PBS) group (*p* \< 0.05)Table 7Analysis of fatty acid composition in abdominal fat of Wistar rats on a high fat diet treated with *G. bimaculatus* extract for 2 monthsComp. of abdomianlfat tissue (%)PBSGB100GB200STAIS100Lauric acid (C12:0)0.04 ± 0.000.05 ± 0.000.05 ± 0.000.05 ± 0.010.06 ± 0.01Myristoleic acid (C14:1)0.02 ± 0.000.02 ± 0.000.02 ± 0.000.02 ± 0.000.02 ± 0.00Myristic acid (C14:0)0.78 ± 0.040.77 ± 0.080.81 ± 0.060.78 ± 0.010.88 ± 0.08Pentadecanoic acid (C15:0)0.13 ± 0.000.14 ± 0.00\*0.14 ± 0.020.15 ± 0.010.15 ± 0.00\*Palmitoleic acid (C16:1)1.74 ± 0.331.98 ± 0.221.93 ± 0.122.08 ± 0.201.86 ± 0.23Palmitic acid (C16:0)19.01 ± 0.5718.85 ± 0.6119.85 ± 1.0518.25 ± 0.9419.57 ± 1.27Heptadecanoic acid (C17:0)0.35 ± 0.040.40 ± 0.030.46 ± 0.030.37 ± 0.030.44 ± 0.03Linoleic acid (C18:2)36.15 ± 1.9140.11 ± 2.2337.26 ± 6.8840.18 ± 0.8938.90 ± 1.91Oleic acid (C18:1)32.10 ± 2.2028.12 ± 0.8028.54 ± 5.6628.88 ± 1.5326.16 ± 1.08Stearic acid (C18:0)8.29 ± 0.458.35 ± 0.699.28 ± 0.337.86 ± 0.6910.16 ± 0.38\*Arachidonic acid (C20:4)0.20 ± 0.040.18 ± 0.050.24 ± 0.020.24 ± 0.040.32 ± 0.07Eicosapentaenoic acid (C20:5)0.04 ± 0.010.03 ± 0.000.04 ± 0.000.03 ± 0.000.04 ± 0.01Eicosatrienoic acid (C20:3)0.08 ± 0.010.06 ± 0.020.08 ± 0.010.08 ± 0.010.09 ± 0.02Eicosadienoic acid (C20:2)0.35 ± 0.020.30 ± 0.070.43 ± 0.030.35 ± 0.020.48 ± 0.11Eicosenoic acid (C20:1)0.56 ± 0.020.49 ± 0.090.65 ± 0.050.54 ± 0.010.69 ± 0.11Eicosanoic acid (C20:0)0.12 ± 0.010.11 ± 0.010.15 ± 0.010.12 ± 0.020.15 ± 0.02Docosahexaenoic acid (C22:6)0.04 ± 0.010.04 ± 0.000.07 ± 0.020.04 ± 0.000.06 ± 0.00Saturated fatty acid28.73 ± 0.0928.67 ± 1.4330.74 ± 1.1627.57 ± 1.6731.39 ± 1.70Unsaturated fatty acid71.27 ± 0.0971.33 ± 1.4369.26 ± 1.1672.43 ± 1.6768.61 ± 1.70Single unsaturated fatty acid34.42 ± 1.9230.60 ± 0.6731.13 ± 5.7131.51 ± 1.7128.73 ± 0.94Poly unsaturated fatty acid36.84 ± 1.8740.73 ± 2.1038.13 ± 6.8640.92 ± 0.9639.88 ± 1.71Comp. of epididymidal fat tissue (%)PBSGB100GB200STAIS100Lauric acid (C12:0)0.06 ± 0.010.06 ± 0.000.07 ± 0.010.06 ± 0.000.09 ± 0.02Myristoleic acid (C14:1)0.04 ± 0.000.05 ± 0.010.04 ± 0.010.03 ± 0.010.06 ± 0.02Myristic acid (C14:0)1.00 ± 0.100.90 ± 0.040.97 ± 0.060.89 ± 0.061.03 ± 0.03Pentadecanoic acid (C15:0)0.17 ± 0.010.19 ± 0.010.19 ± 0.010.16 ± 0.010.19 ± 0.01Palmitoleic acid (C16:1)2.44 ± 0.293.18 ± 0.922.61 ± 0.353.06 ± 0.312.57 ± 0.47Palmitic acid (C16:0)18.63 ± 0.2718.43 ± 1.4119.53 ± 0.3819.97 ± 0.5818.71 ± 0.72Heptadecanoic acid (C17:0)0.36 ± 0.040.38 ± 0.050.41 ± 0.020.39 ± 0.020.38 ± 0.03Linoleic acid (C18:2)39.26 ± 1.1539.86 ± 0.9836.49 ± 2.1336.59 ± 1.1634.77 ± 3.41Oleic acid (C18:1)28.85 ± 1.5727.56 ± 0.9629.85 ± 1.8129.92 ± 1.3532.79 ± 3.43Stearic acid (C18:0)7.50 ± 0.226.96 ± 1.477.71 ± 0.297.06 ± 0.417.44 ± 0.72Arachidonic acid (C20:4)0.32 ± 0.020.56 ± 0.06\*0.48 ± 0.070.40 ± 0.080.47 ± 0.07Eicosapentaenoic acid (C20:5)0.05 ± 0.010.08 ± 0.030.07 ± 0.020.05 ± 0.020.05 ± 0.02Eicosatrienoic acid (C20:3)0.11 ± 0.010.17 ± 0.02\*0.15 ± 0.020.14 ± 0.020.15 ± 0.02Eicosadienoic acid (C20:2)0.46 ± 0.010.51 ± 0.010.52 ± 0.040.51 ± 0.020.46 ± 0.06Eicosenoic acid (C20:1)0.56 ± 0.020.62 ± 0.070.58 ± 0.020.58 ± 0.030.54 ± 0.09Eicosanoic acid (C20:0)0.09 ± 0.010.09 ± 0.030.08 ± 0.000.09 ± 0.010.12 ± 0.01\*Docosahexaenoic acid (C22:6)0.10 ± 0.010.37 ± 0.08\*0.24 ± 0.050.11 ± 0.040.19 ± 0.06Saturated fatty acid27.80 ± 0.3327.03 ± 3.0028.96 ± 0.6628.61 ± 0.9127.96 ± 1.19Unsaturated fatty acid72.20 ± 0.3372.97 ± 3.0071.04 ± 0.6671.39 ± 0.9172.04 ± 1.19Single unsaturated fatty acid31.89 ± 1.3931.41 ± 1.8133.09 ± 1.6633.59 ± 1.3535.96 ± 3.81Poly unsaturated fatty acid40.31 ± 1.1041.57 ± 1.1937.95 ± 2.1437.80 ± 1.2436.08 ± 3.37Each value represents mean ± SEAsterisk marks (\*) mean significant differences compared with control (PBS) group (*p* \< 0.05)

In abdominal GB100 or GB200 fat tissue of 1-month treatment period, mono (single) unsaturated fatty acid composition was decreased whereas poly unsaturated fatty acid composition was increased with dose-dependent manner (each group *vs* CON, *p* \< 0.05). In epididymidal fat tissue of GB100 or GB200 HFD rats of 1-month treatment period, the composition of docosahexaenoic acid in epdidymidal fat tissue showed dose-dependent decrease with significant difference (Gb200 *vs* CON, *p* \< 0.05). In 1-month treatment groups, eicosapentaenoic acid and docosahexaenoic acid composition were increased with statistical significance (GB100 *vs* CON, *p* \< 0.05; STA *vs* CON, *p* \< 0.05).

In abdominal fat of 2-month treated HFD rats, poly unsaturated fatty acid were increased, and monounsaturated fatty acid were dose-dependently decreased (each group *vs* CON, *p* \< 0.05). Stearic acid composition in IS100 group was higher compared with control group (IS100 *vs* CON, *p* \< 0.05).

In epididymidal fat of 2-month treated rats, arachidonic acid and docosahexaenoic acid composition in GB100 (GB100 *vs* CON, *p* \< 0.05), and eicosanoic acid composition in IS100 showed significant differences compared with control (IS100 *vs* CON, *p* \< 0.05).

Discussion {#Sec12}
==========

A high-fat diet (HFD) induces obesity and obesity related metabolic complications such as adipose inflammation, hepatic steatosis and hyperlipidemia \[[@CR13]\]. Among various animal sources tested \[[@CR14]\], cricket extract was found to be a potent functional food; the adipose tissue fat weight of Wistar rats treated with GB over a 2-month period was decreased, especially the abdominal fat and epididymidal fat. However, body weight was not significantly different in the GB treated and control groups.

Modulating inflammation in adipose tissue ameliorates obesity-associated metabolic complications \[[@CR15]\]. GB extract slightly lowered blood pressure and creatinine phosphokinase or otherwise increased thrombin time, showing anticoagulant activity. Repair of protein oxidative damage caused by a high fat diet, carbonyl content and lipid oxidative damage (malondialdehyde, MDA) were decreased by GB treatment \[[@CR16]\]. Hepatic mRNA expression of IL-10 was reported to be increased in obese C57BL6/J mice on high-fat diets \[[@CR17]\] and overexpression of IL-10 prevented weight gain in animals on HFD \[[@CR18]\].

A high-fat diet decreases energy expenditure and the expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodeling- and inflammation-related genes \[[@CR19]\].

This study observed meaningful gene expression profiles. Compared to the control, the GB extract-treated rat group (at a dose of 100 and 200 mg/kg) had 190 up-regulated genes including Gpm6a (glycoprotein m6a) \[[@CR20]\], Tmem14a (transmembrane protein 14A) \[[@CR21]\] and Fasin (fatty acid synthase) \[[@CR22]\] (Table [3](#Tab3){ref-type="table"}) and 235 down-regulated genes including Cc121b (chemokine ligand 21b), Glycan1 (glycosylation dependent cell adhesion molecule \[[@CR23]\], Serpinb1a (serine proteinase inhibitor) \[[@CR24]\] and Tcrb (T-cell receptor beta chain) \[[@CR16]\] (Table [4](#Tab4){ref-type="table"}).

In accordance with the decreased weight of abdominal fat tissue, total cholesterol, LDL-cholesterol, and triglyceride in GB treated rats were lower than those of the control (PBS treated) group. In the sera of rats treated with GB for 1-month, free fatty acid levels were reduced in a dose-dependent manner. In addition, glucose, triglyceride and alkine phosphatase levels were also decreased in the 100 mg/kg GB extract-treated group. The composition of saturated fatty acid was decreased, while unsaturated fatty acid and poly unsaturated fatty acid were increased in the epididymal adipose tissue, suggesting that a diet rich in poly-unsaturated fatty acid decreases adipose tissue mass and suppresses the development of obesity in rats \[[@CR3], [@CR25]\].

Conclusions {#Sec13}
===========

GB demonstrated anti-lipidemic effects in Wistar high fat dieted rats by significantly reducing serum triglyceride and alkaline phosphatase levels. Consequently, GB may be a protective nutraceutical for atherosclerosis disorders, including circulatory disorders. The gene expression profile of high fat dieted Wistar rats treated with GB is a valuable prognostic marker that can be used to identify potential therapeutic targets for atherosclerosis.

Materials and methods {#Sec14}
=====================

Materials {#Sec15}
---------

*G. bimaculatus* was reared in a cricket farm located in Jungsun, Kangwon-Do, South Korea. The cricket was freeze-dried at the Department of Agricultural Biology, National Academy of Agricultural Science, Korea.

Preparation of G. bimaculatus extract (GB) {#Sec16}
------------------------------------------

Dried *G. bimaculatus* (1 kg) was homogenized and soaked then extracted three times with 70 % ethanol by ultrasonification for 30 min. The samples were filtered through Whatman filter paper and concentrated by evaporation and freeze-drying. The dried powder (ethanol extract, GB) was dissolved in saline prior to use in the test solution. *Isaria sinclairii* was also extracted with 70 % ethanol through sonication, evaporation and freeze-drying using the same method as for GB.

Animals {#Sec17}
-------

Han Tac Sam-WH (Wistar) rats (male), weighing 308.0 ± 11.0 g at 14-weeks of age, were obtained from Samtako Co. Ltd. (Osan, Korea) and divided into five groups of ten rats including the Wistar control group. All procedures were in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals. All experiments were approved by the Laboratory Animals' Ethical Committee of the National Academy of Agricultural Science, RDA and followed national guidelines for the care and use of animals (individual housing). The rats were acclimated for four weeks under normal husbandry conditions (23 ± 2 °C, 55 ± 10 %, humidity and 12 h light/dark cycle) and fed a high (60 %) fat diet, D12492 (Research Diet Inc., USA) and water *ad libitum*. The rats were distributed into the following 5 groups (*n* = 10) with similar weights: I: control group, PBS treatment, II: treated with 100 mg/kg *G. bimaculatus* ethanol extract, III: treated with 200 mg/kg *G. bimaculatus* ethanol extract, IV: treated with 2 mg/kg Pravastatin (CJ Heathcare CO., Korea), V: 100 mg/kg *Isaria sinclairii* ethanol extract. Each group (5 sample groups) was maintained for a one month or two month- period (Scheme [1](#Sch1){ref-type="fig"}).

Organ weights {#Sec18}
-------------

About five groups named CON, GB100, GB200, STA, IS100, divided 1 month- or 2 month- period subgroup (*n* = 5). The absolute and relative (organ-to-body weight ratios) weights of the following organs were measured: adrenal glands, kidneys, heart, liver, lung, spleen, stomach, pancreas, thymus and ovaries.

Blood sampling and blood, plasma, serum assay {#Sec19}
---------------------------------------------

On five groups named CON, GB100, GB200, STA, IS100, divided 1 month- or 2 month-period subgroup (*n* = 5), after 1 month of treatment, blood (\~3 ml) was collected from the posterior vena cava under light CO~2~ inhalation and used for serum chemistry measurements. The parameters examined included total protein, total bilirubin, glucose, glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), γ-glutamyl transferase (GGT), alkaline phosphatase (ALP), CK(creatinine phosphokinase), lactic dehydrogenase (LDH), total cholesterol, HDL cholesterol, LDL cholesterol, blood urea nitrogen (BUN), creatinine, triglyceride, uric acid, sodium, potassium and chloride. All parameters were evaluated using an autoanalyzer (Hitachi 7060 automatic clinical analyzer, Tokyo).

Liver homogenate preparation for oxidative damage detection {#Sec20}
-----------------------------------------------------------

About five groups named CON, GB100, GB200, STA, IS100, divided 1 month- or 2 month- period subgroup (*n* = 5), liver tissues were homogenized on ice in a 10-fold volume lysis buffer PRO-PREP™ Protein extraction solution (*i*NtRON, Busan, Korea). The supernatant of the liver homogenate after centrifugation (800 g, 10 min) was assayed for carbonyl content or catalase activity.

Oxidative protein damage (carbonyl content and catalase) quantitation {#Sec21}
---------------------------------------------------------------------

On the supernatant of liver homogenate and blood of five groups named CON, GB100, GB200, STA, IS100, divided 1 month- or 2 month- period subgroup (*n* = 3), the carbonyl content was determined with an enzyme-linked immunoassay according to the manufacturer's protocol for the OxiSelect™ protein carbonyl ELISA kit, Cell Biolabs, Inc. (Sandiego, USA). Catalase activity (CAT, U/mg protein) was measured according to the method based on CAT-mediated decomposition of H~2~O~2~. Potassium phosphate buffer (50 mM, pH 7.0, 0.9 ml) was added to 0.1 ml of the sample followed by H~2~O~2~ solution (1 ml, 30 mM). The decrease in the absorbance at 240 nm was measured for 90 s \[[@CR26]\].

Oxidative lipid damage (malondialdehyde) quantitation {#Sec22}
-----------------------------------------------------

On five groups named CON, GB100, GB200, STA, IS100, divided 1 month- or 2 month- period subgroup (*n* = 3), to determine the oxidative lipid damage in GB treated rat hepatocytes, malondialdehyde (MDA) levels were measured with a lipid peroxidation assay using the color method involving thiobarbituric acid reactive substances (TBARS) at 535 nm. The liver homogenate (0.5 ml) mentioned earlier as well as sodium dodecyl sulfate (7 % SDS, 1 ml) was incubated for 30 min at 37 °C before mixing with TBA (0.67 %, 2 ml, 1: 1 with acetic acid) and adding to tubes. The tubes were mixed, placed in boiling water (100 °C) for 50 min then mixed with butanol (5 ml). 1,1,3,3-tetraethoxypropane was used as a standard \[[@CR27]\].

Cytokine IL-10 assay: R&D kit {#Sec23}
-----------------------------

On five groups named CON, GB100, GB200, STA, IS100, divided 1 month- or 2 month- period subgroup (*n* = 3), the IL-10 level in GB extract-treated rat serumwas measured using commercial ELISA kits (Quantikine, R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer's instructions.

DNA microarray procedure {#Sec24}
------------------------

After histopathology analysis, microarray hybridization was performed on liver samples (Control, GB 100 and GB200). The total RNA was isolated from the liver using a Qiagen RNeasy Midi Kit (Qiagen, Valencia, USA). A regular microarray was carried out according to the manufacturer's instructions for the FairPlay™ microarray labeling kit (Stratagene, La Jolla, CA). Briefly, 20 μg total RNA from the liver was reverse-transcribed into single stranded cDNA. The cDNA was purified with ethanol precipitation and resuspended in 5 μl of 2x coupling buffer, then coupled with 5 μl of Cy3 or Cy5 dye for 1 h in the dark. The labeled control liver cDNA and the treated liver cDNA were combined and purified. The labeled cDNA was mixed with 1.5 μl of 10 μg/μl salmon DNA, 1.5 μl of 8 μg/μl poly d(A), 1.5 μl of 4 μg/μl yeast tRNA, 4.5 μl of 20x SSC and 0.75 μl of 10 % SDS, heated at 99 °C for 2 min, and incubated at 45 °C for 15 min. The labeled DNA was loaded onto a microarray chip. A hybridization chamber was assembled with the microarray chip and submerged in a water bath overnight at 60 °C. The microarray chip was washed in wash buffer I (2x SSC, 0.1 % SDS) for 15 min, then in wash buffer II (1x SSC) for 5 min and in wash buffer III (0.2x SSC) for 15 min. The slide was dried by centrifuging at 500 g for 15 min and scanned with a BMS Array Scanner, applied precision Array WoRx eBiochip Reader (BioRad, Dallas, USA) using the Cy3 and Cy5 channels \[[@CR28]\].

Analysis of fatty acid composition in rat adipose tissue {#Sec25}
--------------------------------------------------------

On five groups named CON, GB100, GB200, STA, IS100, divided 1 month- or 2 month- period subgroup (*n* = 4), for epididymidal and abdominal fat analysis, the concentrations of free fatty acids and fatty acid composition were analyzed for 29 fatty acids in adipose tissue using gas chromatography-mass spectroscopy (GC-MS). Each cut adipose or epididymidal tissue (0.1 g) was collected and extracted overnight bwith a chloroform: methanol (2:1) mixture. The filtered solution was removed under nitrogen gas. The lipids were then saponified by alkaline hydrolysis of phospholipids at 100 °C with 0.5 N methanolic sodium hydroxide and methylated at 100 °C with 14 % BF~3~ for 15 min. The top layer was transferred to petroleum ether and analyzed by GC/MS (Aglient 6890GC, Aglient 5973 N mass detector, EI mode) with a HP-5 capillary column (Aglient Technolgies, Palto alto, Ca, USA). The inlet temperature was 250 °C and the MS transfer line was kept constant at 230 °C. The oven temperature was held at 180 °C for 20 min, then programmed at 10 °C/min to 230 °C and held for 10 min. Quantification was achieved using a mixed 37 fatty acid standard: Sigma L9405, 10 ρg/mL (Sigma-Aldrich Inc.). Linoleic acid (C18:2n6) was used as an internal standard.

Statistical analysis {#Sec26}
--------------------

The means and standard error of all parameters studied were determined for each group using the ANOVA test. A Student's *t*-test was carried out to determine significant differences between control and treated groups. A *p* value \<0.05 was considered significant.

ALP

:   Alkaline phosphatase

ALT(GPT)

:   Glutamate pyruvate transaminase

AST(GOT)

:   Glutamate oxaloacetate transaminase

BUN

:   Blood urea nitrogen

Ca

:   Calcium

CK

:   Creatinine phosphokinase

Cl

:   Chloride

CRP

:   C-reactive protein

FFA

:   Free fatty acid

GB

:   *Gryllus bimaculatus* ethanol extract

GB100

:   *Gryllus bimaculatus* ethanol extract 100 mg/kg

GB200

:   *Gryllus bimaculatus* ethanol extract 200 mg/kg

GGT

:   γ-glutamyl transferase

H. Chol

:   High cholesterol

HFD

:   High-fat diet

Hct

:   Hematocrit

Hgb

:   Hemoglobin

l.Chol

:   Low cholesterol

IP

:   Inorganic phosphorus

IS100

:   *I. sinclairii* ethanol extract 100 mg/kg

LDH

:   Lactate dehydrogenase

MCH

:   Mean corpuscular hemoglobin

MCHC

:   Mean corpuscular hemoglobin concentration

MCV

:   Mean corpuscular volume

K

:   Potassium

Na

:   Sodium

T. Chol

:   Total cholesterol

TG

:   Triglyceride

PLT

:   Partial thromboplastin time

STA

:   Provastastin

PT

:   Prothrombin time

RBC

:   Red blood cell

T. Bil

:   Total bilirubin

WBC

:   White blood cell

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

MY Ahn performed most of the experiments, prepared the manuscript: conceived of the study, participated in its design and coordination, collected and analyzed data, and drafted the manuscript. MJ Kim carried out the animal studies, participated in the fatty acid analysis and oxidative relating enzyme assay. RH Kwon carried out the MDA and catalase assays. JS Hwang participated in the genetic sequence alignment. KK Park participated in DNA microarray. All authors read and approved the final manuscript.

This work was supported by the Rural Development Administration National Research project, PJ009827.
